PDF(Pubmed)
Abstract：
This study aimed to explore the correlation between Fibroblast Growth Factor-23 (FGF23) levels and Cerebral Infarction (CI), and to determine whether there is a significant relationship between FGF23 and the occurrence and severity of CI.
The study categorized Cerebral Infarction (CI) patients into severe and mild stenosis groups based on vertebrobasilar artery stenosis, using Digital Subtraction Angiography (DSA) and Magnetic Resonance Imaging (MRI). The study compared the levels of Fibroblast Growth Factor-23 (FGF23) in the serum of CI patients and healthy controls using a t-test and evaluated the diagnostic effectiveness of serum FGF23 using a Receiver Operating Characteristic (ROC) curve. Additionally, the study analyzed the correlation between FGF23 levels and CI severity after treatment using the National Institute of Health Stroke Scale score.
The study found a significant increase in serum Fibroblast Growth Factor-23 (FGF23) levels in patients with Cerebral Infarction (CI) compared to healthy volunteers, (p < 0.001). A higher serum FGF23 level was observed in the severe stenosis group than in the mild stenosis group (p < 0.001). Furthermore, the study showed that a high FGF23 level at admission was significantly related to more severe symptoms of CI as indicated by the National Institute of Health Stroke Scale (NIHSS) score on the 7th day after treatment (p < 0.001).
This study discovered a correlation between Fibroblast Growth Factor-23 (FGF23) levels, vertebrobasilar artery stenosis, and short-term prognosis in patients who had recently experienced acute Cerebral Infarction (CI).
The study categorized Cerebral Infarction (CI) patients into severe and mild stenosis groups based on vertebrobasilar artery stenosis, using Digital Subtraction Angiography (DSA) and Magnetic Resonance Imaging (MRI). The study compared the levels of Fibroblast Growth Factor-23 (FGF23) in the serum of CI patients and healthy controls using a t-test and evaluated the diagnostic effectiveness of serum FGF23 using a Receiver Operating Characteristic (ROC) curve. Additionally, the study analyzed the correlation between FGF23 levels and CI severity after treatment using the National Institute of Health Stroke Scale score.
The study found a significant increase in serum Fibroblast Growth Factor-23 (FGF23) levels in patients with Cerebral Infarction (CI) compared to healthy volunteers, (p < 0.001). A higher serum FGF23 level was observed in the severe stenosis group than in the mild stenosis group (p < 0.001). Furthermore, the study showed that a high FGF23 level at admission was significantly related to more severe symptoms of CI as indicated by the National Institute of Health Stroke Scale (NIHSS) score on the 7th day after treatment (p < 0.001).
This study discovered a correlation between Fibroblast Growth Factor-23 (FGF23) levels, vertebrobasilar artery stenosis, and short-term prognosis in patients who had recently experienced acute Cerebral Infarction (CI).
摘要：
目的：本研究旨在探讨成纤维细胞生长因子-23（FGF23）水平与脑梗死（CI）的相关性。并确定FGF23与CI的发生和严重程度之间是否存在显着关系。
方法：该研究根据椎基底动脉狭窄将脑梗死（CI）患者分为重度和轻度狭窄组，使用数字减影血管造影（DSA）和磁共振成像（MRI）。该研究使用t检验比较了CI患者和健康对照血清中成纤维细胞生长因子-23（FGF23）的水平，并使用受试者工作特征（ROC）曲线评估了血清FGF23的诊断有效性。此外,本研究使用美国国立卫生研究院卒中量表评分分析FGF23水平与治疗后CI严重程度之间的相关性.
结果：研究发现，与健康志愿者相比，脑梗死（CI）患者的血清成纤维细胞生长因子-23（FGF23）水平显着增加，（p<0.001）。在重度狭窄组中观察到血清FGF23水平高于轻度狭窄组(p<0.001)。此外，研究表明,入院时FGF23水平较高与治疗后第7天美国国立卫生研究院卒中量表(NIHSS)评分显示的更严重的CI症状显著相关(p<0.001).
结论：这项研究发现成纤维细胞生长因子-23（FGF23）水平之间存在相关性，椎基底动脉狭窄,以及最近经历过急性脑梗死（CI）的患者的短期预后。
方法：该研究根据椎基底动脉狭窄将脑梗死（CI）患者分为重度和轻度狭窄组，使用数字减影血管造影（DSA）和磁共振成像（MRI）。该研究使用t检验比较了CI患者和健康对照血清中成纤维细胞生长因子-23（FGF23）的水平，并使用受试者工作特征（ROC）曲线评估了血清FGF23的诊断有效性。此外,本研究使用美国国立卫生研究院卒中量表评分分析FGF23水平与治疗后CI严重程度之间的相关性.
结果：研究发现，与健康志愿者相比，脑梗死（CI）患者的血清成纤维细胞生长因子-23（FGF23）水平显着增加，（p<0.001）。在重度狭窄组中观察到血清FGF23水平高于轻度狭窄组(p<0.001)。此外，研究表明,入院时FGF23水平较高与治疗后第7天美国国立卫生研究院卒中量表(NIHSS)评分显示的更严重的CI症状显著相关(p<0.001).
结论：这项研究发现成纤维细胞生长因子-23（FGF23）水平之间存在相关性，椎基底动脉狭窄,以及最近经历过急性脑梗死（CI）的患者的短期预后。
